A review of NeuroAiDTM II (MLC901) development in Alzheimer’s disease treatment: promises of a multimodal pathway
Background: Alzheimer’s disease (AD) is a clinical and economic burden on society. Without new treatment, the impact of AD on society could triple by 2050. Aim: After a brief overview of treatments and challenges of new drug developments for AD, we reviewed the preclinical and clinical development...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Published: |
Scientific Research and Community Ltd
2022
|